NASDAQ · BLLN
Healthcare · Medical - Diagnostics & Research
$110.45
Up+$2.80 (+2.54%)
Updated Nov 4, 2026, 8:52 PM
SID Score
6.3/10
Composite research score
Smart Money
58/100
Neutral
Price performance · BLLN
1M range · 21 trading sessions · Daily adjusted prices
Prices through Nov 3, 2026
BLLN closed at $110.45 after 21 trading sessions, up 10.52% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 3, 2026 | $110.63 | $113.42 | $109.56 | $110.45 | 360.92K |
| Nov 2, 2026 | $113.17 | $114.0736 | $106.72 | $110.41 | 635.92K |
| Oct 30, 2026 | $113.29 | $114.02 | $110.42 | $113.32 | 468.31K |
| Oct 29, 2026 | $114.02 | $115.20 | $112.67 | $114.84 | 583.18K |
| Oct 28, 2026 | $113.96 | $119.20 | $113.11 | $114.00 | 453.43K |
| Oct 27, 2026 | $111.84 | $115.92 | $110.05 | $114.07 | 372.36K |
| Oct 26, 2026 | $108.00 | $111.58 | $106.285 | $111.465 | 404.78K |
| Oct 23, 2026 | $106.11 | $108.99 | $102.8901 | $107.77 | 482.39K |
| Oct 22, 2026 | $104.34 | $105.97 | $102.00 | $105.68 | 377.83K |
| Oct 21, 2026 | $103.27 | $107.04 | $102.80 | $104.67 | 377.59K |
| Oct 20, 2026 | $101.12 | $104.67 | $99.55 | $103.50 | 398.67K |
| Oct 19, 2026 | $98.95 | $102.50 | $98.234 | $101.03 | 462.78K |
| Oct 16, 2026 | $101.41 | $102.57 | $96.21 | $98.12 | 605.95K |
| Oct 15, 2026 | $97.18 | $102.93 | $93.441 | $102.73 | 427.23K |
| Oct 14, 2026 | $93.375 | $99.75 | $93.375 | $97.88 | 424.93K |
| Oct 13, 2026 | $91.81 | $96.00 | $90.48 | $94.44 | 664.22K |
| Oct 12, 2026 | $97.61 | $97.61 | $91.22 | $93.07 | 491.52K |
| Oct 9, 2026 | $94.46 | $100.31 | $94.46 | $98.09 | 325.04K |
| Oct 8, 2026 | $94.06 | $96.015 | $91.01 | $95.41 | 386.3K |
| Oct 7, 2026 | $99.42 | $99.85 | $94.52 | $95.75 | 679.89K |
| Oct 6, 2026 | $107.86 | $112.8699 | $98.90 | $99.94 | 1.12M |
The latest Smart Investors Daily articles mentioning BLLN.
Company
Market Activity
Research & News
BLLN research
Company profile and research snapshot.
BillionToOne Inc is a precision diagnostics company revolutionizing molecular testing with its patented Quantitative Counting Templates (QCT) platform. This technology enables ultrasensitive, single-molecule DNA quantification, making genetic testing more accurate, affordable, and accessible. The company serves prenatal screening and oncology markets with non-invasive tests that detect fetal genetic risks and monitor cancer therapy response.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 1, 2026 | Guggenheim | Buy | — |
| Sep 2, 2026 | Canaccord Genuity | Buy | — |
| Aug 6, 2026 | JP Morgan | Overweight | — |
| Aug 6, 2026 | BTIG | Buy | — |
| Jun 29, 2026 | Guggenheim | Buy | — |
No generated briefing is available yet.
Yahoo · Oct 29, 2026
Baxter (BAX) delivered earnings and revenue surprises of +13.73% and +2.48%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
Yahoo · Oct 29, 2026
Investing.com-- Several specialty lab companies are set to report third-quarter results in early November, with analysts at BTIG outlining key metrics and expectations for the sector’s leading names. The firm has identified three stocks positioned for potential upside, though each faces distinct tests as investors scrutinize guidance, volume trends, and strategic updates.
Yahoo · Oct 28, 2026
BillionToOne (BLLN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Yahoo · Oct 27, 2026
MENLO PARK, Calif., Oct. 27, 2026 (GLOBE NEWSWIRE) -- BillionToOne, Inc. (NASDAQ: BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, today announced that the Company will participate in two upcoming investor conferences. UBS Global Healthcare Conference 2026Fireside Chat on Tuesday, November 10th at 2:00 PM ET Stifel 2026 Healthcare ConferenceFireside Chat on Wednesday, November 11th at 3:20 PM ET A live and arc
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning BLLN.
